PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143371
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143371
Monocyte Activation Test Market size was valued at US$ 620.8 Million in 2025, expanding at a CAGR of 15.8% from 2026 to 2033.
Monocyte Activation Test, also known as MAT, are laboratory pyrogen tests that exist between endotoxin tests and broader safety checks. They use whole blood, blood mononuclear cells, or special monocytic cells to determine if inflammation occurs when endotoxins or other pyrogens are present. This test is important for medicines injected into the body, biopharmaceuticals, vaccines, and medical devices that must show no pyrogens before they are released. The way the test is sold depends on how the cell source is qualified, which cytokines are measured, how the product is validated, and whether standard kits and reagents are available. A major change occurred on July 1, 2025: the European Pharmacopoeia updated its rules regarding pyrogenicity and removed the old rabbit test from 57 updated texts. This shift made MAT less of a method and more of a central part of today's pyrogen control strategies.
Monocyte Activation Test Market- Market Dynamics
Regulatory Replacement of Animal-Based Pyrogen Testing
The strongest market-specific catalyst is the shift away from the rabbit pyrogen test toward scientifically supported in vitro methods. Starting July 1, 2025, the European Pharmacopoeia updated its pyrogenicity framework, requiring medicine developers to choose an in vitro strategy that matches their product's risk profile. Among the options, MAT was clearly identified as one approach. This change moves the focus from buying a pyrogen assay to building a validated and transferable testing workflow that can be used in routine quality control. As a result, suppliers are distinguishing themselves by offering cells, easier protocols, automation tools, and new ways to read results. Take Minerva Biolabs' 2025 NAT-MAT system, for example-it uses PCR instead of traditional ELISA for cytokine measurement. This demonstrates how regulation is driving changes not just in process but also in product design. The outcome is a growing move toward standardized and operationally efficient MAT platforms, not just simple assay parts.
The Global Monocyte Activation Test Market is segmented on the basis of Product Type, Application, Source, End User, and Region.
By product type, the product split shows how laboratories balance flexibility with workflow standardization. Reagents remain important in settings where skilled analytical teams prefer to customize cell preparation, stimulation, cytokine detection, and controls based on their existing lab protocols. In contrast, MAT kits bundle these components into a structured testing system that makes method transfer easier and supports routine release testing. This difference matters most as labs shift from development experiments to verified quality control processes. Merck's PyroMAT, for example, combines MAT reagents with IL-6 ELISA-based detection methods, showing a trend toward fully integrated testing instead of relying on separate consumables. As a result, product differences are increasingly based on reproducibility, cell qualification, documentation, and ease of use. Kits are becoming workflow solutions while reagents continue to offer more control at the lab level.
By application, the needs of each use case drive how MAT systems are set up and validated. The pyrogenic profile of a product varies depending on whether it is in development or release. In medical device testing, the focus is on extraction techniques and how well the method works with different device materials. In drug development, the system must manage formulation interference during both analytical development and release steps. Vaccine development presents another challenge because some vaccine ingredients naturally exhibit activity, meaning endotoxin-only testing isn't enough. A 2025 Merck study tested an MAT for an outer-membrane-protein vaccine across relative pyrogenicity levels from 25% to 300% compared to a reference lot, showing how application-specific validation affects assay design. This means the application structure favors platforms that can adjust validation strategies to match the biological traits of each product.
Monocyte Activation Test Market- Geographical Insights
Europe has become the reference point for MAT because its pharmacopoeial framework has moved beyond merely allowing alternative pyrogen testing. The European Pharmacopoeia's updated framework became effective on July 1, 2025, while the specific rabbit pyrogen chapter was later planned for removal in January 2026. The framework does not require MAT as the replacement; developers must instead use risk assessments to choose a suitable in vitro method, with MAT listed as one of the main alternatives. This difference is important commercially because laboratories need methods that are backed by product verification and strong technical documentation instead of just purchasing an assay. Europe, therefore, acts as a validation center, pushing suppliers to align cell systems, readouts, and documentation with Ph. Eur. 2.6.30 requirements.
Asia-Pacific is taking on a role through research, development of alternative testing, and local technology platforms. Korean researchers released a specific MAT review in March 2025 covering regulatory approval, validation, pharmaceutical testing, and medical-device applications, with input from the University of Seoul, Daegu Gyeongbuk Medical Innovation Foundation, and the National Institute of Food and Drug Safety Evaluation. Japan is also creating technology around standardized monocytic cells: NEDO's 2025 program highlights Kyoto-based MiCAN Technologies' development of MylcMAT products using immortalized aMylc cells as a supported deep-tech research theme. This mix of research and local cell-platform development gives the region a strong position in reducing reliance on donor-derived systems and making assays more consistent.
Competition is moving away from pyrogen detection toward better control of biological variability, higher assay sensitivity, shorter workflow times, and greater scalability. Suppliers differentiate themselves through cell sources, standardized monocytic lines, cytokine readouts, and integrated validation support. For example, CTL - MAT states that its manufacturing network can supply up to 2,000 vials of pooled cryopreserved PBMCs per batch, which solves one of the limitations that arise from maintaining a consistent cell supply across testing programs. Other suppliers are pursuing technology architectures: Minerva uses digital PCR and standardized HL - 60 - derived cells, while MiCAN is developing immortalized monocyte systems that aim to improve reproducibility and supply stability. The competitive boundary is therefore shifting toward scalable testing platforms rather than conventional reagent supply alone.
In April 2025, Minerva Biolabs launched the NAT-MAT(R) System. This system combines monocyte activation testing with PCR for pyrogen detection. The company stated that the workflow uses 4 hours of cell stimulation instead of the overnight stimulation used in conventional ELISA-based MAT workflows.
In September 2025, Merck researchers published a reporter-cell MAT designed for the release testing of vaccines that contain inherently pyrogenic components. The validation study was carried out in 14 experiments. The study found repeatability and intermediate precision of 6.9 percent RSD.